Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors

NCT06932094 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

256

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: QLS5132

Sponsor

Qilu Pharmaceutical Co., Ltd.